Skip to main content


Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 7 | Journal of Neuroinflammation

Fig. 7

From: Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor

Fig. 7

Cell viability measured in cultured M-213 cells treated with different concentrations of VCE-003.2 (0.1, 0.5, and 1.0 μM) or RGZ (20 μM) in the presence or the absence of T0070907 (10 μM) and exposed to conditioned media generated from LPS-stimulated BV2 cells. The control (100% of cell viability) consisted in M-213 cells that were exposed to conditioned media in the absence of LPS. Values are means ± SEM of at least 4 independent experiments each performed in duplicate. Data were assessed by the one-way analysis of variance followed by the Student–Newman–Keuls test (*p < 0.05, **p < 0.01, ***p < 0.005 compared to the control cells (incubated with conditioned media no generated with LPS); @p < 0.05, @@p < 0.01 versus cells treated with RGZ, as well as versus cells treated with VCE-003.2 (0.1 and 0.5 μM) combined or not with T0070907 (incubated with conditioned media generated with LPS))

Back to article page